Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Stock Has Average Target Price of $13.80 According to Analysts

Key Points

• Analysts rate Iovance a “Moderate Buy” overall: Nine of 14 analysts recommend buying, one recommends a strong buy, three rate it hold, and one says sell. The average 12-month price target is $13.80.
• Third-quarter results beat expectations: Revenue was about $121.5 million, up 64.8% year over year, and the loss per share was narrower than forecast. Amtagvi U.S. revenue rose about 77% year over year, while gross margin reached a company record of 60%.
• Pipeline prospects are mixed: Lifileucel received FDA Fast Track designation for potential use in sarcoma, while NSCLC trial results were mixed, with a 24.6% response rate overall and a higher rate in a biomarker-selected subgroup.

Shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Get Free Report) have been given an average recommendation of "Moderate Buy" by the fourteen ratings firms that are covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation, nine have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $13.80.

Several analysts have recently issued reports on the stock. Wells Fargo & Company upped their target price on shares of Iovance Biotherapeutics from $14.00 to $18.00 and gave the company an "overweight" rating in a research report on Wednesday, September 30th. TD Cowen lifted their price target on Iovance Biotherapeutics from $7.00 to $10.00 and gave the stock a "buy" rating in a research report on Monday, August 24th. Barclays lifted their price target on Iovance Biotherapeutics from $18.00 to $19.00 and gave the stock an "overweight" rating in a research report on Friday. Weiss Ratings reissued a "sell (d-)" rating on shares of Iovance Biotherapeutics in a research note on Tuesday, September 29th. Finally, Zacks Research upgraded Iovance Biotherapeutics from a "hold" rating to a "strong-buy" rating in a research report on Monday, October 26th.

Iovance Biotherapeutics News Roundup

Here are the key news stories impacting Iovance Biotherapeutics this week:

• Positive Sentiment: Iovance reported record third-quarter revenue of about $122 million, beating estimates, while its loss of $0.05 per share was narrower than the expected $0.09. Amtagvi U.S. revenue grew about 77% year over year, gross margin reached a company-record 60%, and management reaffirmed its 2026 revenue outlook. These results point to growing commercial traction and improving economics. Iovance third-quarter results
• Positive Sentiment: Barclays raised its price target from $18 to $19 and kept an “overweight” rating; Citizens JMP raised its target from $8 to $12 and maintained a “market outperform” rating. The upgrades reflect more optimistic analyst views on IOVA’s prospects. Barclays ratings Citizens JMP ratings
• Positive Sentiment: Lifileucel received FDA Fast Track designation following promising sarcoma trial data, potentially supporting development in an additional cancer indication. Lifileucel Fast Track news
• Negative Sentiment: NSCLC results were mixed: the objective response rate was 24.6% across 69 evaluable patients, slightly below a prior interim result. That may temper expectations for this opportunity, although a biomarker-selected subgroup showed a higher 59.1% response rate and a trial is underway. Iovance clinical outlook

Iovance Biotherapeutics Stock Performance

IOVA stock opened at $8.04 on Friday. The firm has a fifty day moving average price of $11.37 and a 200 day moving average price of $5.97. Iovance Biotherapeutics has a fifty-two week low of $2.08 and a fifty-two week high of $15.37. The firm has a market cap of $3.64 billion, a PE ratio of -15.17 and a beta of 0.88.

Iovance Biotherapeutics (NASDAQ:IOVA - Get Free Report) last released its quarterly earnings results on Thursday, November 5th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.09) by $0.04. Iovance Biotherapeutics had a negative net margin of 58.20% and a negative return on equity of 30.68%. The company had revenue of $121.47 million for the quarter, compared to the consensus estimate of $115.98 million. The business's revenue was up 64.8% on a year-over-year basis. On average, equities analysts predict that Iovance Biotherapeutics will post -0.43 EPS for the current year.

Hedge Funds Weigh In On Iovance Biotherapeutics

Several large investors have recently modified their holdings of IOVA. Clearwater Capital Advisors LLC bought a new position in Iovance Biotherapeutics in the third quarter worth approximately $322,000. Russell Investments Group Ltd. grew its position in Iovance Biotherapeutics by 165.7% during the 3rd quarter. Russell Investments Group Ltd. now owns 513,032 shares of the biotechnology company's stock worth $7,603,000 after purchasing an additional 319,979 shares during the last quarter. Brighton Jones LLC lifted its stake in shares of Iovance Biotherapeutics by 5.1% during the third quarter. Brighton Jones LLC now owns 40,069 shares of the biotechnology company's stock worth $594,000 after buying an additional 1,954 shares during the period. Pictet Asset Management Holding SA grew its holdings in shares of Iovance Biotherapeutics by 867.6% during the third quarter. Pictet Asset Management Holding SA now owns 416,539 shares of the biotechnology company's stock valued at $6,043,000 after buying an additional 373,491 shares during the last quarter. Finally, Kestra Advisory Services LLC grew its stake in Iovance Biotherapeutics by 25.2% during the 3rd quarter. Kestra Advisory Services LLC now owns 42,150 shares of the biotechnology company's stock valued at $625,000 after purchasing an additional 8,483 shares during the last quarter. Institutional investors own 77.03% of the company's stock.

About Iovance Biotherapeutics

Iovance Biotherapeutics, Inc NASDAQ: IOVA is a biotechnology company focused on developing and commercializing personalized cell therapies for patients with cancer. Its technology is based on tumor-infiltrating lymphocytes (TILs), immune cells collected from a patient's tumor, expanded outside the body, and reinfused to help attack cancer cells.

The company's lead product, Amtagvi (lifileucel), is an autologous TIL therapy approved in the United States for certain adults with unresectable or metastatic melanoma that has progressed following prior treatment.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.